Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1968 1
1970 1
1971 1
1974 1
1975 3
1977 9
1978 5
1979 1
1980 4
1981 5
1982 7
1983 8
1984 7
1985 10
1986 6
1987 4
1988 8
1989 9
1990 12
1991 7
1992 10
1993 13
1994 20
1995 19
1996 18
1997 24
1998 16
1999 24
2000 19
2001 15
2002 21
2003 17
2004 21
2005 21
2006 25
2007 30
2008 31
2009 33
2010 37
2011 46
2012 47
2013 47
2014 66
2015 47
2016 73
2017 65
2018 54
2019 56
2020 45
2021 50
2022 39
2023 43
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

1,072 results

Results by year

Filters applied: . Clear all
Page 1
Clinical and Radiological Features of Interstitial Lung Diseases Associated with Polymyositis and Dermatomyositis.
Palmucci S, Di Mari A, Cancemi G, Pennisi I, Mauro LA, Sambataro G, Sambataro D, Galioto F, Fazio G, Ferlito A, Pino F, Basile A, Vancheri C. Palmucci S, et al. Medicina (Kaunas). 2022 Nov 30;58(12):1757. doi: 10.3390/medicina58121757. Medicina (Kaunas). 2022. PMID: 36556960 Free PMC article. Review.
Polymyositis and dermatomyositis are autoimmune idiopathic systemic inflammatory diseases, characterized by various degrees of muscle inflammation and typical cutaneous lesions-the latter found in dermatomyositis. ...The interstitial lung disease occurs in one-third of …
Polymyositis and dermatomyositis are autoimmune idiopathic systemic inflammatory diseases, characterized by various degrees of muscle …
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, García-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation. Aggarwal R, et al. Ann Rheum Dis. 2017 May;76(5):792-801. doi: 10.1136/annrheumdis-2017-211400. Ann Rheum Dis. 2017. PMID: 28385805 Free PMC article.
To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. ...Consensus was reached for a conjoint analysis-based continuous mod …
To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). Expert surveys, logistic regression, and conjoint …
Polymyositis and dermatomyositis biomarkers.
Xu S, Hu X, Wang J, Xu Q, Han Z, Zhou H, Gao M. Xu S, et al. Clin Chim Acta. 2023 Jul 1;547:117443. doi: 10.1016/j.cca.2023.117443. Epub 2023 Jun 15. Clin Chim Acta. 2023. PMID: 37329941 Review.
Polymyositis (PM) and dermatomyositis (DM) are the two subtypes of idiopathic inflammatory myositis and are characterized as symmetrical progressive muscle weakness in the proximal extremities. ...An in-depth understanding of PM/DM biomarkers will facilitate development of …
Polymyositis (PM) and dermatomyositis (DM) are the two subtypes of idiopathic inflammatory myositis and are characterized as symmetri …
Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).
Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW. Rider LG, et al. Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11(0 11):S118-57. doi: 10.1002/acr.20532. Arthritis Care Res (Hoboken). 2011. PMID: 22588740 Free PMC article. Review. No abstract available.
Idiopathic inflammatory myositis.
Tieu J, Lundberg IE, Limaye V. Tieu J, et al. Best Pract Res Clin Rheumatol. 2016 Feb;30(1):149-68. doi: 10.1016/j.berh.2016.04.007. Epub 2016 May 26. Best Pract Res Clin Rheumatol. 2016. PMID: 27421222 Review.
In this paper, we outline key advances in diagnosis and histopathology, including the more recent identification of antibodies associated with immune-mediated necrotising myopathy (IMNM) and inclusion body myositis (IBM). Ongoing longitudinal observational cohorts allow fu …
In this paper, we outline key advances in diagnosis and histopathology, including the more recent identification of antibodies associated wi …
Advances in biomarkers for dermatomyositis.
Yang WM, Chen JJ. Yang WM, et al. Clin Chim Acta. 2018 Jul;482:172-177. doi: 10.1016/j.cca.2018.03.042. Epub 2018 Mar 31. Clin Chim Acta. 2018. PMID: 29614309 Review.
Dermatomyositis (DM) and polymyositis (PM) are heterogeneous complex autoimmune diseases involving muscle damage. ...Our aim is to focus on novel biomarkers for diagnosing and monitoring disease activity in DM and PM to highlight their predictive value and applicabi …
Dermatomyositis (DM) and polymyositis (PM) are heterogeneous complex autoimmune diseases involving muscle damage. ...Our aim is to fo …
Idiopathic inflammatory myopathies.
Dimachkie MM, Barohn RJ. Dimachkie MM, et al. Front Neurol Neurosci. 2009;26:126-146. doi: 10.1159/000212374. Epub 2009 Apr 6. Front Neurol Neurosci. 2009. PMID: 19349710 Review.
Bohan and Peter in 1975 established diagnostic criteria for polymyositis and dermatomyositis. Subsequent investigations by Arahata and Engel delineated differences in the lymphocyte subsets on muscle histopathology distinguishing polymyositis and dermatomyositis. .. …
Bohan and Peter in 1975 established diagnostic criteria for polymyositis and dermatomyositis. Subsequent investigations by Arahata an …
Risk of Malignancy in Dermatomyositis and Polymyositis.
Qiang JK, Kim WB, Baibergenova A, Alhusayen R. Qiang JK, et al. J Cutan Med Surg. 2017 Mar/Apr;21(2):131-136. doi: 10.1177/1203475416665601. Epub 2016 Aug 20. J Cutan Med Surg. 2017. PMID: 27534779 Review.
BACKGROUND: There is variation in the risk of malignancy in dermatomyositis (DM) and polymyositis (PM) in the existing literature. OBJECTIVE: To conduct a meta-analysis to estimate the risk of malignancy in DM and PM as compared with the general population. METHODS: Medlin …
BACKGROUND: There is variation in the risk of malignancy in dermatomyositis (DM) and polymyositis (PM) in the existing literature. OB …
A machine learning analysis to evaluate the outcome measures in inflammatory myopathies.
Danieli MG, Paladini A, Longhi E, Tonacci A, Gangemi S. Danieli MG, et al. Autoimmun Rev. 2023 Jul;22(7):103353. doi: 10.1016/j.autrev.2023.103353. Epub 2023 May 2. Autoimmun Rev. 2023. PMID: 37142194 Free article. Review.
We considered different parameters, including clinical manifestations and organ involvement, number and type of treatments, serum creatine kinase levels, muscle strength (MMT8 score), disease activity (MITAX score), disability (HAQ-DI score), disease damage ( …
We considered different parameters, including clinical manifestations and organ involvement, number and type of treatments, serum creatine k …
Malignancy in myositis.
Zahr ZA, Baer AN. Zahr ZA, et al. Curr Rheumatol Rep. 2011 Jun;13(3):208-15. doi: 10.1007/s11926-011-0169-7. Curr Rheumatol Rep. 2011. PMID: 21336621 Review.
Factors predictive of malignancy in myositis patients include more severe skin and muscle disease and the absence of overlap connective tissue disease features, such as interstitial lung disease. Anti-p155/140 antibodies have a strong predictive value for malignancy …
Factors predictive of malignancy in myositis patients include more severe skin and muscle disease and the absence of overlap connecti …
1,072 results